Actinium Pharmaceuticals
ATNM
42 hedge funds and large institutions have $2.09M invested in Actinium Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 6 closing their positions.
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.07% less ownership
Funds ownership: 0.29% → 0.22% (-0.07%)
7% less funds holding
Funds holding: 45 → 42 (-3)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
33% less capital invested
Capital invested by funds: $3.12M → $2.09M (-$1.03M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$196K |
| 2 |
Renaissance Technologies
New York
|
+$46.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$16.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$15.6K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$10.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$628K |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$197K |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$147K |
| 4 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$43K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$23.1K |
ATNM Hedge Fund Activity: Q1 2020 in Review
42 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q1 2020, worth a combined $2.09M — down 33% from $3.12M a quarter earlier.
Fund positioning in ATNM was balanced in Q1 2020: 6 funds opened new positions, 6 closed out, 8 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $196K. The largest seller was Sabby Management, cutting an estimated $628K.
- 42 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q1 2020, down from 45 in Q4 2019.
- Funds reported $2.09M of Actinium Pharmaceuticals stock for Q1 2020, down 33% quarter-over-quarter.
- 6 funds opened new Actinium Pharmaceuticals positions in Q1 2020 and 6 closed out, a net change of 0 holders.
- The largest Actinium Pharmaceuticals buyer in Q1 2020 was BlackRock, an estimated $196K added.
- The largest Actinium Pharmaceuticals seller in Q1 2020 was Sabby Management, an estimated $628K sold.
Based on aggregated 13F filings for Q1 2020.